
Prevent the Event
Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.1
Deze website is uitsluitend voorbehouden aan beroepsbeoefenaren in Nederland.


Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.1

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Think Fabry, think timely testing first.

Think Fabry, think regular profile-based assessments.

Cardiovascular disease is the leading cause of death in fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think screening at-risk family members.1


Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2